PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting
Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who unde...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=3;spage=417;epage=426;aulast=Rojo-Arnao |
| _version_ | 1797246473934471168 |
|---|---|
| author | María Rojo-Arnao José María Martinez-de-la-Casa Oscar Albis-Donado Giovanni Yañez-Castro Raquel Maroto-Cejudo Jesús Téllez Ricardo Menoyo-Calatayud |
| author_facet | María Rojo-Arnao José María Martinez-de-la-Casa Oscar Albis-Donado Giovanni Yañez-Castro Raquel Maroto-Cejudo Jesús Téllez Ricardo Menoyo-Calatayud |
| author_sort | María Rojo-Arnao |
| collection | DOAJ |
| description | Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6–15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months (P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg (P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg (P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population (P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety. |
| first_indexed | 2024-04-24T19:43:22Z |
| format | Article |
| id | doaj.art-ba7e827bdd1a4610b7a10c681343b014 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-04-24T19:43:22Z |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-ba7e827bdd1a4610b7a10c681343b0142024-03-25T10:28:45ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892024-01-0172341742610.4103/IJO.IJO_1502_23PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical settingMaría Rojo-ArnaoJosé María Martinez-de-la-CasaOscar Albis-DonadoGiovanni Yañez-CastroRaquel Maroto-CejudoJesús TéllezRicardo Menoyo-CalatayudPurpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6–15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months (P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg (P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg (P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population (P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=3;spage=417;epage=426;aulast=Rojo-Arnaoglaucomaglaucoma surgeryintraocular pressuremigsologenpreserflo microshunt |
| spellingShingle | María Rojo-Arnao José María Martinez-de-la-Casa Oscar Albis-Donado Giovanni Yañez-Castro Raquel Maroto-Cejudo Jesús Téllez Ricardo Menoyo-Calatayud PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting Indian Journal of Ophthalmology glaucoma glaucoma surgery intraocular pressure migs ologen preserflo microshunt |
| title | PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_full | PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_fullStr | PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_full_unstemmed | PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_short | PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_sort | preserflotm microshunt implantation combined with ologentm in primary and secondary glaucoma patients in a clinical setting |
| topic | glaucoma glaucoma surgery intraocular pressure migs ologen preserflo microshunt |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=3;spage=417;epage=426;aulast=Rojo-Arnao |
| work_keys_str_mv | AT mariarojoarnao preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT josemariamartinezdelacasa preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT oscaralbisdonado preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT giovanniyanezcastro preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT raquelmarotocejudo preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT jesustellez preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting AT ricardomenoyocalatayud preserflotmmicroshuntimplantationcombinedwithologentminprimaryandsecondaryglaucomapatientsinaclinicalsetting |